Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study.
Lancet Glob Health. 2020; 8: e1003-e1017
A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19.
Sci Rep. 2021; 118562
COVID-19 in people with diabetes: understanding the reasons for worse outcomes.
Lancet Diabetes Endocrinol. 2020; 8: 782-792
Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics.
Int J Obes. 2021; 45: 1163-1169
Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies.
Diabetes Metab Syndr. 2020; 14: 809-814
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.
BMJ. 2020; 369m1985
Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis.
Diabetes Metab Syndr. 2021; 15: 813-822
Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis.
Diabetes Obes Metab. 2020; 22: 1915-1924
Global pandemics interconnected – obesity, impaired metabolic health and COVID-19.
Nat Rev Endocrinol. 2021; 17: 135-149
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.
Immunity. 2021; 54: 1578-1593
Obesity could shift severe COVID-19 disease to younger ages.
Lancet. 2020; 395: 1544-1545
Consequences of the COVID-19 pandemic for patients with metabolic diseases.
Nat Metab. 2021; 3: 289-292
COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes.
Diabetes Care. 2021; 44: 526-532
Why inequality could spread COVID-19.
Lancet Public Health. 2020; 5: e240
COVID-19: Obesity, deprivation and death.
J Glob Health. 2020; 10020389
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.
Clin Microbiol Infect. 2021; ()
Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge.
J Clin Med. 2021; 102945
Unraveling the mystery surrounding post-acute sequelae of COVID-19.
Front Immunol. 2021; 12686029
ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.
Br J Pharmacol. 2013; 169: 477-492
The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
Pharmacol Res. 2017; 125: 21-38
The renin-angiotensin-aldosterone system and coronavirus disease 2019.
Eur Cardiol. 2021; 16: e07
Practical recommendations for the management of diabetes in patients with COVID-19.
Lancet Diabetes Endocrinol. 2020; 8: 546-550
Effects of taurine on ACE, ACE2 and HSP70 expression of hypothalamic-pituitary-adrenal axis in stress-induced hypertensive rats.
Adv Exp Med Biol. 2017; 975: 871-886
SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells.
Cell Metab. 2020; 32: 1028-1040.e4
Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19.
Cell Metab. 2020; 32: 1041-1051.e6
ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection.
Clin Gastroenterol Hepatol. 2020; 18: 2128-2130.e2
SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature.
Front Endocrinol (Lausanne). 2020; 11596898
SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas.
Nat Metab. 2021; 3: 149-165
SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment.
Cell Metab. 2021; 33: 1565-1576.e5
Viral infiltration of pancreatic islets in patients with COVID-19.
Nat Commun. 2021; 123534
Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients.
Med Hypotheses. 2020; 144110271
Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
J Endocrinol. 2020; 247: R45-R62
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?.
Lancet Respir Med. 2020; 8: e21
Dexamethasone in hospitalized patients with COVID-19.
N Engl J Med. 2021; 384: 693-704
Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA.
Mol Metab. 2020; 32: 160-167
A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Eur Heart J Cardiovasc Pharmacother. 2021; 7: 148-157
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.
Nat Commun. 2020; 112070
DPP-4 inhibitors and severe course of illness in patients with COVID-19.
Therapie. 2021; 76: 359-360
Therapeutic potential of metformin in COVID-19: reasoning for its protective role.
Trends Microbiol. 2021; ()
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
Lancet Diabetes Endocrinol. 2021; 9: 293-303
Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?.
J Diabetes Complications. 2020; 34107723
Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.
Biochem Biophys Res Commun. 2020; 524: 332-339
Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis.
Ther Adv Endocrinol Metab. 2021; 12 ()
Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19.
Diabetes Metab J. 2021; 45: 251-259
Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.
Lancet Reg Health Eur. 2021; ()
Diabetes, obesity, COVID-19, Insulin, and other antidiabetes drugs.
Diabetes Care. 2021; 44: 1929-1933
Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes.
Cell Metab. 2021; 33: 65-77
Renin-angiotensin-aldosterone system blockers and the risk of COVID-19.
N Engl J Med. 2020; 382: 2431-2440
Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19).
JAMA Cardiol. 2020; 5: 1020-1026
Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19.
Circ Res. 2020; 126: 1671-1681
The plasmatic aldosterone and c-reactive protein levels, and the severity of COVID-19: the Dyhor-19 study.
J Clin Med. 2020; 9E2315
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
Cell. 2020; 181: 271-280.e8
Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.
Cell. 2020; 181: 281-292.e6
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
Science. 2021; 372eabg3055
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.
Science. 2021; 372: 815-821
Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020.
Euro Surveill. 2021; 262002106
Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data.
J Cell Physiol. 2021; 236: 7045-7057
Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein.
Heliyon. 2021; 7e06564
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Nature. 2020; 581: 215-220
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
Science. 2020; 370: 856-860
Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection.
Cell. 2021; 184: 76-91
Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes.
Cell. 2021; 184: 149-168
Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19.
Crit Care. 2020; 24: 484
Regulated cell death and inflammation: an auto-amplification loop causes organ failure.
Nat Rev Immunol. 2014; 14: 759-767
The MERS-CoV Receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike.
iScience. 2020; 23101160
Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Crit Rev Clin Lab Sci. 2003; 40: 209-294
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
Endocr Rev. 2014; 35: 992-1019
Coronavirus Infections and type 2 diabetes-shared pathways with therapeutic implications.
Endocr Rev. 2020; 41bnaa011
The impact of obesity on severe disease and mortality in people with SARS-CoV-2: a systematic review and meta-analysis.
Endocrinol Diabetes Metab. 2020; 4e00176
A metabolic handbook for the COVID-19 pandemic.
Nat Metab. 2020; 2: 572-585
Causes, consequences, and treatment of metabolically unhealthy fat distribution.
Lancet Diabetes Endocrinol. 2020; 8: 616-627
COVID-19 and the heart.
Circ Res. 2020; 126: 1443-1455
COVID-19 presenting as stroke.
Brain Behav Immun. 2020; 87: 115-119
Insulin receptor signaling in normal and insulin-resistant states.
Cold Spring Harb Perspect Biol. 2014; 6a009191
How the association between obesity and inflammation may lead to insulin resistance and cancer.
Diabetes Metab Syndr. 2019; 13: 1213-1224
Macrophage function in obesity-induced inflammation and insulin resistance.
Pflugers Arch. 2017; 469: 385-396
Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications.
Diabetol Metab Syndr. 2021; 13: 23
Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation.
PLoS One. 2015; 10e0133494
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.
Diabetes Res Clin Pract. 2014; 105: 141-150
Blood sugar regulation for cardiovascular health promotion and disease prevention: JACC health promotion series.
J Am Coll Cardiol. 2018; 72: 1829-1844
Regulation of adrenocortical function by cytokines–relevance for immune-endocrine interaction.
Horm Metab Res. 1998; 30: 416-420
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis.
Mol Psychiatry. 2020; 25: 1611-1617
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Lancet Respir Med. 2021; 9: 763-772
Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection.
Lancet Diabetes Endocrinol. 2020; 8: 472-473
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.
J Biol Regul Homeost Agents. 2020; 34: 327-331
Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: case series.
Curr Ther Res Clin Exp. 2020; 93100609
Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID-19 infection.
Am J Emerg Med. 2020; 38: 2491e3-2491e4
Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report.
Nat Metab. 2020; 2: 1021-1024
COVID-19 infection may cause ketosis and ketoacidosis.
Diabetes Obes Metab. 2020; 22: 1935-1941
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.
Nat Metab. 2021; 3: 774-785
New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19.
J Pediatr Endocrinol Metab. 2020; 34: 147-150
New-onset diabetes in COVID-19.
N Engl J Med. 2020; 383: 789-790
Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany.
JAMA. 2020; 324: 801-804
New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic.
Arch Dis Child. 2021; ()
Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP).
BMJ Case Rep. 2020; 13e237903
Can COVID-19 cause diabetes?.
Nat Metab. 2021; 3: 123-125
Adhering to COVID-19 health guidelines: examining demographic and psychological predictors of adherence.
Appl Psychol Health Well-Being. 2021; ()
COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncertainties and challenges.
Diabetes Metab Syndr. 2021; 15: 505-508
The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation.
Diabetologia. 2021; 64: 1184-1186
The European perspective of diabetes prevention: the need for individualization of diabetes prevention.
J Endocrinol Invest. 2013; 36: 352-357
Diabetes management during coronavirus.
Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic.
Diabet Med. 2021; 38e14469
Diabetes-related amputations: a pandemic within a pandemic.
J Am Podiatr Med Assoc. 2020; ()
Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals.
Diabetes Metab Syndr. 2020; 14: 965-967
The impact of COVID-19 restrictions on accelerometer-assessed physical activity and sleep in individuals with type 2 diabetes.
Diabet Med. 2021; ()
Diabetes and COVID-19: population impact 18 months into the pandemic.
Diabetes Care. 2021; 44: 1916-1923
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.
Lancet Diabetes Endocrinol. 2021; 9: 82-93
A post COVID-19 ‘Marshall Plan’ for type 2 diabetes.
Diabet Med. 2021; 38e14439
Psychological crisis intervention for COVID-19 lockdown stress in patients with type 1 diabetes mellitus: survey study and qualitative analysis.
JMIR Ment Health. 2021; 8e28097
Increased stress, weight gain and less exercise in relation to glycemic control in people with type 1 and type 2 diabetes during the COVID-19 pandemic.
BMJ Open Diabetes Res Care. 2021; 9e002035
Stress and physical inactivity: two explosive ingredients for the heart in COVID-19 pandemic times.
Curr Cardiol Rev. 2021; ()
Pharmacological management of COVID-19 in type 2 diabetes.
J Diabetes Complications. 2021; 35107927
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Diabetes Endocrinol. 2021; 9: 586-594
Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO study.
Diabetes Res Clin Pract. 2021; 175108695
Association between DPP-4 inhibitors and COVID-19-related outcomes among patients with type 2 diabetes.
Diabetes Care. 2021; 44: e64-e66
Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and covid-19: a multicenter, case-control, retrospective, observational study.
Diabetes Care. 2020; 43: 2999-3006
Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis.
J Med Virol. 2021; 93: 695-697
Metformin and COVID-19: from cellular mechanisms to reduced mortality.
Diabetes Metab. 2020; 46: 423-426
Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes.
Cell Metab. 2020; 32: 537-547
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet. 2021; 397: 1637-1645
Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis.
Clin Exp Rheumatol. 2019; 37: 465-473
Negative impact of hyperglycaemia on tocilizumab therapy in COVID-19 patients.
Diabetes Metab. 2020; 46: 403-405
Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.
Diabetologia. 2020; 63: 1440-1452
Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: meta-analysis A.
JAMA. 2020; 324: 1330-1341
J Diabetes. 2014; 6: 9-20
FDA expands remote patient monitoring in hospitals for people with diabetes during COVID-19; manufacturers donate CGM supplies.
Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes.
Cell Metab. 2020; 31: 1068-1077
Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis.
Diabetes Care. 2021; 44: 578-585
Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study.
Diabetes Care. 2021; 44: 549-555
Altered lipid metabolism in recovered SARS patients twelve years after infection.
Sci Rep. 2017; 79110
Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes.
Acta Diabetol. 2010; 47: 193-199
Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study.
BMC Neurol. 2011; 11: 37
COVID-19 and chronic fatigue syndrome: is the worst yet to come?.
Med Hypotheses. 2021; 146110469
High-dimensional characterization of post-acute sequelae of COVID-19.
Nature. 2021; 594: 259-264
The Stanford Hall consensus statement for post-COVID-19 rehabilitation.
Br J Sports Med. 2020; 54: 949-959
The adrenal gland in stress – adaptation on a cellular level.
J Steroid Biochem Mol Biol. 2019; 190: 198-206
Experiences, opinions and expectations of health care providers towards an intensive care unit follow-up clinic: Qualitative study and online survey.
Intensive Crit Care Nurs. 2021; ()
Infect Dis Clin North Am. 2021; 35: 435-452
Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum.
J Laryngol Otol. 2021; 135: 442-447
Long COVID – metabolic risk factors and novel therapeutic management.
Nat Rev Endocrinol. 2021; 17: 379-380
Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study.
BMJ. 2021; 372: n693
Prevalence of people at risk of developing type 2 diabetes mellitus and the involvement of community pharmacies in a national screening campaign: a pioneer action in Brazil.
Diabetol Metab Syndr. 2020; 12: 89
Diabetes mellitus in India: the modern scourge.
Med J Armed Forces India. 2009; 65: 50-54
Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults.
Eur J Epidemiol. 2013; 28: 169-180
Coronavirus in Africa: five reasons why COVID-19 has been less deadly than elsewhere.
What should governments be doing to prevent diabetes throughout the life course?.
Diabetologia. 2019; 62: 1842-1853
Digital health surveillance strategies for management of coronavirus disease 2019.
Mayo Clin Proc Innov Qual Outcomes. 2021; 5: 109-117
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Trials. 2021; 22: 39
A quantitative estimation of the pancreatic islet tissue1.
QJM. 1937; 6: 287-300
Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
Diabetes Obes Metab. 2021; 23: 910-915
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
Lancet. 2021; 396: 2019-2082